These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 973988)

  • 21. Combined administration of 5-HT2 and thromboxane A2 antagonists: effects on platelet aggregation and isolated cardiac muscle.
    Shaw LA; Batey AJ; Coker SJ
    Br J Pharmacol; 1997 Jul; 121(5):875-82. PubMed ID: 9222543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fluphenazine decanoate and fluphenazine enanthate in the out-patient management of chronic schizophrenia.
    MacCrimmon DJ; Saxena B; Foley P; Grof P
    Neuropsychobiology; 1978; 4(6):360-5. PubMed ID: 692838
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Platelet aggregation and chlorpromazine therapy.
    Boullin DJ; Know JM; Peters JR; Orr MW; Gelder MG; Grahame-Smith DG
    Br J Clin Pharmacol; 1978 Dec; 6(6):538-40. PubMed ID: 728326
    [No Abstract]   [Full Text] [Related]  

  • 24. Inhibition of 5-hydroxytryptamine-potentiated aggregation of human blood platelets by 5-hydroxytryptamine receptor-blocking agents.
    Glusa E; Markwardt F
    Biomed Biochim Acta; 1984; 43(2):215-20. PubMed ID: 6732757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months' treatment for relapse prevention.
    Kissling W; Möller HJ; Walter K; Wittmann B; Krueger R; Trenk D
    Pharmacopsychiatry; 1985 May; 18(3):240-5. PubMed ID: 4011672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Positive and negative symptoms, depression and social disability in chronic schizophrenia: a comparative trial of bromperidol and fluphenazine decanoates.
    McLaren S; Cookson JC; Silverstone T
    Int Clin Psychopharmacol; 1992 Nov; 7(2):67-72. PubMed ID: 1487623
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of omega-3 fatty acid on platelet serotonin responsivity in patients with schizophrenia.
    Yao JK; Magan S; Sonel AF; Gurklis JA; Sanders R; Reddy RD
    Prostaglandins Leukot Essent Fatty Acids; 2004 Sep; 71(3):171-6. PubMed ID: 15253886
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An open clinical trial with the long-acting neuroleptics flupenthixol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia.
    Kong DS; Yeo SH
    Pharmatherapeutica; 1989; 5(6):371-9. PubMed ID: 2687894
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pretreatment with serotonin 5-HT(3) receptor antagonists produces no observable blockade of long-term motor sensitization to cocaine in rats.
    Szumlinski KK; Frys KA; Kalivas PW
    Psychopharmacology (Berl); 2003 Feb; 165(4):329-36. PubMed ID: 12451437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship between the behavioral and electroencephalographic effects of chlorpromazine and fluphenazine in rats.
    Babbini M; Gaiardi M; Bartoletti M
    Pharmacology; 1975; 13(6):520-5. PubMed ID: 1221434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Abnormal platelet aggregation in patients with Raynaud's phenomenon.
    Biondi ML; Marasini B
    J Clin Pathol; 1989 Jul; 42(7):716-8. PubMed ID: 2760232
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroleptic drug-induced changes in platelet levels.
    Holt RJ
    J Clin Psychopharmacol; 1984 Jun; 4(3):130-2. PubMed ID: 6145727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and toxicological profile of fluphenazine decanoate in elderly chronic schizophrenia.
    Altamura AC; Mauri MC; Girardi T; Panetta B
    Int J Clin Pharmacol Res; 1990; 10(4):223-8. PubMed ID: 2079381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blunted serotonergic responsivity in neuroleptic-naïve patients at first-episode of schizophrenia.
    Reddy R; Keshavan M; Yao JK
    Schizophr Res; 2007 Feb; 90(1-3):81-5. PubMed ID: 17204398
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fluphenazine decanoate: a clinical problem?
    Inderbitzin LB; Lewine RR; Gloersen BA; Rosen PB; McDonald SC; Vidanagama BP
    Am J Psychiatry; 1989 Jan; 146(1):88-91. PubMed ID: 2563210
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of a selective 5-HT2 receptor antagonist (ICI 170,809) on platelet aggregation and pupillary responses in healthy volunteers.
    Millson DS; Jessup CL; Swaisland A; Haworth S; Rushton A; Harry JD
    Br J Clin Pharmacol; 1992 Mar; 33(3):281-8. PubMed ID: 1576048
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum neuroleptic levels and clinical outcome in schizophrenic patients treated with fluphenazine decanoate.
    Brown WA; Silver MA
    J Clin Psychopharmacol; 1985 Jun; 5(3):143-7. PubMed ID: 3998204
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Shape change and aggregation of blood platelets: interaction between the effects of adenosine and diphosphate, 5-hydroxytryptamine and adrenaline.
    Michal F; Motamed M
    Br J Pharmacol; 1976 Feb; 56(2):209-18. PubMed ID: 1252669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics: a systematic chart review.
    Uchida T; Suzuki T; Sakurai H; Tsutsumi C; Den R; Mimura M; Uchida H
    Int Clin Psychopharmacol; 2013 Sep; 28(5):261-6. PubMed ID: 23820334
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Platelet function after the administration of chlorpromazine to human subjects.
    Warlow C; Ogston D; Douglas AS
    Haemostasis; 1976; 5(1):21-6. PubMed ID: 1269995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.